Senior Division Manager (West Coast)

Remote

Apply with AI Apply

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

A Bachelor's degree is required, with an advanced degree preferred. Candidates must have at least 10 years of biotech/pharma sales experience, including a minimum of 3 years in a sales leadership role. Proven experience in hematology/oncology and/or cell therapy markets is essential, along with inspirational leadership, strong communication, coaching, and team development skills. An innovative and strategic mindset with experience in building and implementing actionable account plans is also necessary. The role requires living within the specified West Coast territory (WA, OR, ID, MT, CA, NV) and entails at least 50% travel.

Responsibilities

The Senior Division Manager will build, lead, and develop a team of seven sales professionals to launch and expand the company's CAR T candidate, anitocabtagene autoleucel. Responsibilities include attracting, retaining, and developing top talent, onboarding and training the team to exceed launch expectations, and leading the team to meet sales and performance goals. The manager will analyze market trends and competitive activity to inform strategy, develop and implement divisional sales plans, and support the team in creating strategic territory and account plans. Additionally, they will proactively engage with key customers to build relationships and advocacy, collaborate with partner Kite Pharma and field stakeholders, and lead the team in executing aligned goals. The role also involves attending and leading commercial activities at scientific meetings and ensuring compliance with all regulatory and legal requirements.

Skills

Sales Management

Team Leadership

Sales Strategy

CAR T Therapy

Biotechnology Sales

Multiple Myeloma

Arcellx

Develops immunotherapies for cell therapy

About Arcellx

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary products and partnerships to drive their research and development efforts. The goal is to meet unmet medical needs by providing safe and effective treatment options through their innovative approach to cell therapy.

Gaithersburg, MarylandHeadquarters

2014Year Founded

$194.5MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Risks

Competition from established CAR-T therapies like Abecma and Carvykti could limit market share.

Dependency on Gilead's Kite partnership poses risks if partnership dynamics change.

Phase 3 iMMagine-3 trial delays or failures could impact anito-cel's market timeline.

Differentiation

Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.

The novel D-Domain binder in anito-cel enhances antigen binding and cell killing.

ARC-SparX offers dosable and controllable CAR-T therapy options.

Upsides

Growing investment in personalized medicine aligns with Arcellx's tailored immunotherapies.

Advancements in gene editing like CRISPR enhance precision in engineered cell therapies.

Outpatient CAR-T administration could reduce costs and increase accessibility for Arcellx.

Land your dream remote job 3x faster with AI

Try Jobo Free